Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SLIT Cisplatin
Cisplatin liposomal · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cisplatin liposomal 24 mg/m2 | EXPERIMENTAL | Inhaled liposomal cisplatin was administered over 1 day in a 14-day treatment cycle by inhalation for a maximum of 6 cycles. |
| Cisplatin liposomal 36 mg/m2 | EXPERIMENTAL | The study allowed for a dose escalation of liposomal cisplatin to 36 mg/m2 if no adverse events of Grade 3 or higher occurred after at least 3 cycles of drug administration at 24 mg/m2 |
| Name | Type | Description |
|---|---|---|
| Cisplatin liposomal | DRUG | - |
Inclusion Criteria: * Histologically proven, Progressive or recurrent high grade osteosarcoma metastatic to the lung * Patients with histologically proven, fully malignant high-grade osteosarcoma of bone * Measureable pulmonary metastases * Less than grade 3 neuropathies, insignificant decreases in...
Cisplatin liposomal is an investigational formulation of the chemotherapy agent cisplatin that is delivered by inhalation. It is being developed by Insmed Incorporated (ticker INSM) for the treatment of osteosarcoma metastatic to the lung. The liposomal form is designed to deliver the drug directly to the lungs.
Cisplatin liposomal is being studied for the treatment of osteosarcoma metastatic to the lung. This is a cancer that has spread from the bone to the lungs. The drug is given by inhalation, targeting the metastatic tumors in the lungs. It is not approved for any use and remains investigational.
Cisplatin liposomal is being developed by Insmed Incorporated, which trades under the ticker symbol INSM. Insmed is a biopharmaceutical company focused on serious and rare diseases. The company has conducted a Phase 1 trial of the inhaled formulation in patients with osteosarcoma metastatic to the lung.
Cisplatin liposomal is in Phase 1 clinical development. One Phase 1 trial has been completed. The drug is investigational and has not been approved by the FDA for any indication. Further clinical testing would be required before any potential regulatory review.
Cisplatin liposomal has been studied in one completed Phase 1 trial, NCT00102531, titled "Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung." The trial enrolled 19 participants in the United States and included patients aged 13 years and older. No active trials are ongoing.